Información del artículo
El Texto completo está disponible en PDF
Bibliograf¿a
[1]
The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2000; 6:21-33.
[2]
Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol. 1991; 86:489-93.
[3]
Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology. 1978; 74:501-3.
[4]
Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut. 1994; 35:669-74.
[5]
Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol. 2003; 98:511-2.
[6]
Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut. 1998; 42:470-6.
[7]
Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000; 51:289-98.
[8]
Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 1994; 106:533-9.
[9]
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119:15-22.
[10]
Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol. 2002; 97:2820-8.
[11]
Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999; 34:50-4.
[12]
Use of technetium-tagged white blood cells in patients with Crohn's disease and ulcerative colitis: is differential diagnosis possible?. Pediatr Radiol. 1998; 28:871-7.
[13]
Otsuka Pharmaceuticals. Adacolumn apheresis treatment in patients with inmune disorders: rationale and summary of results. Reino Unido: Otsuka Pharmaceuticals, 2005.
[14]
Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003; 7:48-59.
[15]
Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004; 49:565-71.
[16]
Leukocyte adsorption and removal for the treatment of ulcerative colitis. Nippon Naika Gakkai Zasshi. 1999; 88:724-30.
[17]
Granulocyte and monocyte adsorptive apheresis in a case with severe ulcerative colitis unresponsive to conventional medication. J Clin Apheresis. 2003; 18:40-2.
[18]
Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther. 2004; 20:783-92.
[19]
Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004; 20:1347-52.
[20]
Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci. 2002; 47:2349-53.
[21]
Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci. 2002; 47:1334-41.
[22]
Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher. 2001; 16:1-9.
[23]
Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial. 2003; 7:48-59.
[24]
Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs. 1997; 21:989-94.
[25]
Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol. 2004; 99:1532-8.
[26]
Granulocyte apheresis as a possible new approach in cancer therapy: a pilot study involving two cases. Cancer Detect Prev. 1999; 23:417-21.
[27]
A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher. 1998; 2:134-41.
[28]
Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol. 2003; 1:28-35.
[29]
Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004; 10:251-7.
[30]
Granulocytapheresis in active ulcerative colitis. A multicenter randomized study. Jpn J Apher. 1999; 18:117-31.
[31]
Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis. 2001; 16:1-9.
[32]
Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004; 70:36-44.
[33]
Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004; 36:811-7.
[34]
Experiencia con la agranulocitoaféresis en la enfermedad de Crohn. Rev Esp Enferm Dig. 2004; 96:501-6.
[35]
The medical management of inlammatory bowel disease in childen. En: Kirsner J.B., editors. Inflammatory bowel disease. Philadelphia: WB Saunders; 2000. 578-97.
[36]
Growth of prepubertal children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998; 26:310-4.
[37]
Growth retardation in children with ulcerative colitis: the effect of medical and surgical therapy. Pediatrics. 1975; 55:459-67.
[38]
Leukocite adsorptie apheresis in paediatric inflammatory bowel disease: safety and tolerance of the technique and preliminary data of efficacy. J Pediatr Gastroenterol Nutr. 2004; 39:S315-6.
[39]
Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci. 2003; 48:750-4.
[40]
Corticorresistencia y corticodependencia en la enfermedad inflamatoria intestinal. En: Esteve-Comas M., Gassull M.A., editors. Enfermedad inflamatoria intestinal. Madrid: Ergon; 2002.
